Being a significant health problem that affects patients in various age groups, breast cancer has been extensively
studied to date. Recently, molecular breast cancer classification has advanced significantly with the availability of
genomic profiling technologies. Proteomic technologies have also advanced from traditional protein assays including enzyme-
linked immunosorbent assay, immunoblotting and immunohistochemistry to more comprehensive approaches including
mass spectrometry and reverse phase protein lysate arrays (RPPA). The purpose of this manuscript is to review
the current protein markers that influence breast cancer prediction and prognosis and to focus on novel advances in proteomic
classification of breast cancer.
Keywords: Breast cancer, proteome, RPPA, molecular technology, genomic profiling, reverse phase protein lysate arrays(RPPA), mass spectrometry, human genome, Epidermal Growth Factor Receptor (EGFR), genomic technologies.
Rights & PermissionsPrintExport